Preserving fertility when choosing chemotherapy regimens – the role of gonadotropin-releasing hormone agonists

Bibliography

• Blumenfeld Z, Katz G, Evron A. ‘An ounce of prevention is worth a pound of cure’: the case for and against GnRH-agonist for fertility preservation. Ann Oncol 2014;25(9):1719-28
   PubMed Web of Science ®Google Scholar
• Siegel R, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29
   PubMed Web of Science ®Google Scholar
• De Vos M, Smitz J, Woodruff TK. Fertility preservation in women with cancer. Lancet 2014;384:1302-10
   PubMed Web of Science ®Google Scholar
• Waimey KE, Duncan FE, Su HI, et al. Future directions in oncofertility and fertility preservation: a report from the 2011 oncofertility consortium conference. J Adolesc Young Adult Oncol 2013;2:25-30
   PubMed Web of Science ®Google Scholar
• Wallace WHB, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol 2005;6:209-18
   PubMed Web of Science ®Google Scholar
• Linkeviciute A, Boniolo G, Chiavari L, Peccatori FA. Fertility preservation in cancer patients: the global framework. Cancer Treat Rev 2014;40:1019-27
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z. Debate: how to preserve fertility in young women exposed to chemotherapy? The role of GnRH-agonist in addition to cryopreservation of embryos, oocytes, or ovaries. Oncologist 2007;12:1044-54
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 2008;14:543-52
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Avivi I, Eckman R, et al. Gonadotropin releasing hormone agonist decreases chemotherapy induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil Steril 2008;89:166-73
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z. GnRH-agonists in fertility preservation. Curr Opin Endocrinol Diabetes Obes 2008;15:523-8
   PubMedGoogle Scholar
• Blumenfeld Z, Zuckerman T. Repeated spontaneous pregnancies and successful deliveries after repeated autologous stem cell transplantation and GnRH-agonist. Oncologist 2010;15:59-60
   PubMed Web of Science ®Google Scholar
• Cardozo ER, Thomson AP, Karmon AE, et al. Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls: a 17-year experience. J Assist Reprod Genet 2015. [ Epub ahead of print]
   PubMedGoogle Scholar
• Revelli A, Porcu E, Levi Setti PE, et al. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol 2013;29:993-6
   PubMed Web of Science ®Google Scholar
• Tomasi-Cont N, Lambertini M, Hulsbosch S, et al. Strategies for fertility preservation in young early breast cancer patients. Breast 2014;23:503-10
   PubMed Web of Science ®Google Scholar
• Dursun P, Doğan NU, Ayhan A. Oncofertility for gynecologic and non-gynecologic cancers: fertility sparing in young women of reproductive age. Crit Rev Oncol Hematol 2014;92:258-67
   PubMedGoogle Scholar
• Nayak SR, Wakim AN. Random-start gonadotropin-releasing hormone (GnRH) antagonist-treated cycles with GnRH agonist trigger for fertility preservation. Fertil Steril 2011;96:e51-4
   PubMed Web of Science ®Google Scholar
• Dolmans MM, Donnez J, Camboni A, et al. IVF outcome in patients with orthotopically transplanted ovarian tissue. Hum Reprod 2009;24:2778-87
   PubMed Web of Science ®Google Scholar
• Dolmans MM, Marinescu C, Saussoy P, et al. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood 2010;116:2908-14
   PubMed Web of Science ®Google Scholar
• Rosendahl M, Andersen MT, Ralfkiær E, et al. Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Fertil Steril 2010;94:2186-90
   PubMed Web of Science ®Google Scholar
• Abir R, Feinmesser M, Yaniv I, et al. Occasional involvement of the ovary in Ewing sarcoma. Hum Reprod 2010;25:1708-12
   PubMed Web of Science ®Google Scholar
• Bittinger SE, Nazaretian SP, Gook DA, et al. Detection of Hodgkin lymphoma within ovarian tissue. Fertil Steril 2011;95:803.e3-6
   Web of Science ®Google Scholar
• Kyono K, Doshida M, Toya M, et al. Potential indications for ovarian autotransplantation based on the analysis of 5,571 autopsy findings of females under the age of 40 in Japan. Fertil Steril 2010;93:2429-30
   PubMed Web of Science ®Google Scholar
• Knight PG, Glister C. TGF-beta superfamily members and ovarian follicle development. Reproduction 2006;132:191-206
   PubMed Web of Science ®Google Scholar
• Roness H, Gavish Z, Cohen Y, Meirow D. Ovarian follicle burnout: a universal phenomenon? Cell Cycle 2013;12:3245-6
   PubMed Web of Science ®Google Scholar
• Del-Mastro L, Levaggi A, Giraudi A, Pronzato P. Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives. Cancer Treat Rev 2011;37:208-11
   PubMedGoogle Scholar
• Del Mastro L, Giraudi S, Levaggi A, Pronzato P. Medical approaches to preservation of fertility in female cancer patients. Expert Opin Pharmacother 2011;12:387-96; Review
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Ceppi M, Poggio F, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev 2014;40:675-83
   PubMed Web of Science ®Google Scholar
• Clowse ME, Behera MA, Anders CK, et al. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009;18:311-19
   PubMed Web of Science ®Google Scholar
• Wong M, O’Neill S, Walsh G, Smith IE. Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. Ann Oncol 2013;24:133-8
   PubMed Web of Science ®Google Scholar
• Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat 2010;122:803-11
   PubMed Web of Science ®Google Scholar
• Kim SS, Lee JR, Jee BC, et al. Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol 2010;53:740-52
   PubMed Web of Science ®Google Scholar
• Bedaiwy MA, Abou-Setta AM, Desai N, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 2011;95:906-14
   PubMed Web of Science ®Google Scholar
• Chen H, Li J, Cui T, et al. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2011(11):CD008018
   PubMed Web of Science ®Google Scholar
• Yang B, Shi W, Yang J, et al. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials. Breast 2013;22:150-7
   PubMed Web of Science ®Google Scholar
• Wang C, Chen M, Fu F, et al. Gonadotropin-releasing hormone analog cotreatment for the preservation of ovarian function during gonadotoxic chemotherapy for breast cancer: a meta-analysis. PLoS One 2013;8:e66360
   PubMed Web of Science ®Google Scholar
• Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995;52:365-72
   PubMed Web of Science ®Google Scholar
• Moore HC. Ovarian failure after chemotherapy for breast cancer and the role of gonadotropin-releasing hormone analogs in protection of ovarian function. In: Moore HC, editor, American Society of Clinical Oncology 2008 educational book. American Society of Clinical Oncology; Alexandria, VA: 2008. p. 39-42
   Google Scholar
• Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011;306:269-76
   PubMed Web of Science ®Google Scholar
• Moore HC, Unger JM, Phillips KA, et al. the POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923-32
   PubMed Web of Science ®Google Scholar
• Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009;117:561-7
   PubMed Web of Science ®Google Scholar
• Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009;91:694-7
   PubMed Web of Science ®Google Scholar
• Behringer K, Thielen I, Mueller H, et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol 2012;23:1818-25
   PubMed Web of Science ®Google Scholar
• Demeestere I, Brice P, Peccatori FA, et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol 2013;31:903-9
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Dann EJ. GnRH agonist for the prevention of chemotherapy-induced ovarian failure in lymphoma. J. Clin Oncology 2013;31:3721
   PubMedGoogle Scholar
• Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol 1987;19:159-62
   PubMed Web of Science ®Google Scholar
• Behringer K, Wildt L, Mueller H, et al. German Hodgkin Study Group. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol 2010;21:2052-60
   PubMed Web of Science ®Google Scholar
• Azem F, Samara N, Cohen T, et al. Assessment of ovarian reserve following ovarian tissue banking and/or GnRH-a co-treatment prior to chemotherapy in patients with Hodgkin’s disease. J Assist Reprod Genet 2008;25:535-8
   PubMed Web of Science ®Google Scholar
• Nitzschke M, Raddatz J, Bohlmann MK, et al. GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin’s lymphoma patients. Arch Gynecol Obstet 2010;282:83-8
   PubMed Web of Science ®Google Scholar
• Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:533-8
   PubMed Web of Science ®Google Scholar
• Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO Study. J Clin Oncol 2011;29:2334-41
   PubMed Web of Science ®Google Scholar
• Leonard RC, Adamson D, Anderson R, et al. The OPTION trial of adjuvant ovarian protection by goserelin in adjuvant chemotherapy for early breast cancer [abstract 590]. J Clin Oncol 2010;28(Suppl):15s
   PubMedGoogle Scholar
• Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013;121:78-86
   PubMed Web of Science ®Google Scholar
• Torino F, Barnabei A, De Vecchis L, et al. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. Crit Rev Oncol Hematol 2014;89:27-42
   PubMed Web of Science ®Google Scholar
• Loren AW, Mangu PB, Beck LN, et al. American Society of Clinical Oncology. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2500-10
   PubMed Web of Science ®Google Scholar
• Practice Committee of American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril 2013;100:1214-23
   PubMed Web of Science ®Google Scholar
• Fleisher LA, Bass EB, McKeown P. Methodological approach. American College of Chest physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 2005;128:17S-23S
   PubMedGoogle Scholar
• Turner NH, Partridge A, Sanna G, et al. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol 2013;24:2224-35
   PubMed Web of Science ®Google Scholar
• Chung K, Donnez J, Ginsburg E, Meirow D. Emergency IVF versus ovarian tissue cryopreservation: decision making in fertility preservation for female cancer patients. Fertil Steril 2013;99:1534-42
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Patel B, Leiba R, Zuckerman T. Gonadotropin Releasing Hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation. Fertil Steril 2012;98:1266-70
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z. Gonadotropin-releasing hormone agonist for preservation of ovarian function during (neo) adjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:3310
   PubMedGoogle Scholar
• Blumenfeld Z. Fertility preservation and GnRHa for chemotherapy: debate. Cancer Manag Res 2014;6:313-15
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z. Comment on: sexual and fertility adverse effects associated with chemotherapy treatment in women. Expert Opin Drug Saf 2014;13:1283-5
   PubMed Web of Science ®Google Scholar
• Remérand G, Merlin E, Froissart R, et al. Four successful pregnancies in a patient with mucopolysaccharidosis type I treated by allogeneic bone marrow transplantation. J Inherit Metab Dis 2009;32(Suppl 1):S111-13
   PubMedGoogle Scholar
• Salooja N, Szydlo RM, Socie G, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet 2001;358:271-6
   PubMed Web of Science ®Google Scholar
• Carter A, Robison LL, Francisco L, et al. Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone Marrow Transplant 2006;37:1023-9
   PubMed Web of Science ®Google Scholar
• Sklar CA, Mertens AC, Mitby P, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006;98:890-6
   PubMed Web of Science ®Google Scholar
• Green DM, Sklar CA, Boice JD, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27:2374-81
   PubMed Web of Science ®Google Scholar
• Edgar AB, Wallace WH. Pregnancy in women who had cancer in childhood. Eur J Cancer 2007;43:1890-4
   PubMed Web of Science ®Google Scholar
• Cuzick J, Ambroisine L, Davidson N, et al. LHRH-agonists in Early Breast Cancer Overview group. Use of luteinizing-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone receptor- positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711-23
   PubMed Web of Science ®Google Scholar
• Recchia F, Candeloro G, Necozione S, et al. Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy. Anticancer Res 2011;31:671-6
   PubMedGoogle Scholar
• Lambertini M, Ginsburg ES, Partridge AH. Update on fertility preservation in young women undergoing breast cancer and ovarian cancer therapy. Curr Opin Obstet Gynecol 2015;27:98-107
   PubMed Web of Science ®Google Scholar
• Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000;342:1878-86
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342:1887-92
   PubMed Web of Science ®Google Scholar
• Meirow D, Rabinovici J, Katz D, et al. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone–releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer 2006;107:1634-41
   PubMed Web of Science ®Google Scholar
• von Wolff M, Montag M, Dittrich R, et al. Fertility preservation in women-a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin’s lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet 2011;284:427-35
   PubMed Web of Science ®Google Scholar
• Donnez J, Dolmans MM. Transplantation of ovarian tissue. Best Pract Res Clin Obstet Gynaecol 2014;28:1188-97
   PubMed Web of Science ®Google Scholar
• Smitz J, Dolmans MM, Donnez J, et al. Current achievements and future research directions in ovarian tissue culture, in vitro follicle development and transplantation: implications for fertility preservation. Hum Reprod Update 2010;16:395-414
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Mischari O, Schultz N, Boulman N, Balbir-Gurman A. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases. Semin Arthritis Rheum 2011;41:346-52
   PubMed Web of Science ®Google Scholar
• Pereyra Pacheco B, Mendez Ribaz JM, Milone G, et al. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: A preliminary report. Gynecol Oncol 2001;81:391-7
   PubMed Web of Science ®Google Scholar
• Somers EC, Marder W, Christman GM, et al. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 2005;52:2761-7
   PubMed Web of Science ®Google Scholar
• Recchia F, Saggio G, Amiconi G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006;106:514-23
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Catzeddu T, Boni L, et al. Prevention of chemotherapy induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 2006;17:74-8
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Nomdedeu B, Camus A, et al. Use of gonadotropin releasing hormone agonists in patients with Hodgkin’s disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril 2007;87:702-5
   PubMed Web of Science ®Google Scholar
• Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L. Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 2007;12:141-7
   PubMed Web of Science ®Google Scholar
• Falorio S, Angrilli F, Fioritoni G. Gonadotropin-releasing hormone analog treatment for the prevention of treatment-related ovarian failure and infertility in women of reproductive age with Hodgkin lymphoma. Leuk Lymphoma 2008;49:1087-93
   PubMed Web of Science ®Google Scholar
• Imai A, Sugiyama M, Furui T, Tamaya T, Ohno T. Direct protection by a gonadotropin-releasing hormone analog from doxorubicin-induced granulosa cell damage. Gynecol Obstet Invest 2007;63:102-6
   PubMed Web of Science ®Google Scholar
• Huser M, Crha I, Ventruba P, Hudecek R, et al. Prevention of ovarian function damage by a GnRH analogue during chemotherapy in Hodgkin lymphoma patients. Hum Reprod 2008;23:863-8
   PubMed Web of Science ®Google Scholar
• Urriticoechea A, Walsh G, Rigg A, et al. Ovarian function protection with goserelin during adjuvant chemotherapy in pre-menopausal women with early breast cancer. Breast Cancer Res Treat 2004;88(suppl 1):S229
   Google Scholar
• Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 2009;91:694-7
   PubMed Web of Science ®Google Scholar